Low molecular weight heparins in the outpatient management of venous thromboembolism

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 97-99

  Bick, Rodger L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; CONFERENCE PAPER; COST CONTROL; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; OUTPATIENT CARE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

AMBULATORY CARE; ANIMALS; DISEASE MANAGEMENT; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0032728132     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bick RL, Kaplan H. Syndromes causing hypercoagulability and thrombosis. Med Clin N Am 1998;82:409-458
2. Van den Belt AGM, Prins MH, Lensing AWA, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. (Cochrane Review) In: The Cochrane Library, Issue 2. Oxford: Update; 1998
3. MedPar: The MedStat Group outcomes analysis. Nashville, TN: MedPar, 1998 Inforum, Medistat, 1998
4. Bergqvist D, Lundblad B. Incidence of venous thromboembolism in medical and surgical patients. In: Bergqvist D, Comerota A, Nicolaides A, Scurr J, eds. Prevention of Venous Thromboembolism. London: Med-Orion Press, 1994
5. Levine M, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996:334:677-681
6. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med I996;334:682-687
7. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparision of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thomb Haemost 1994;72:186-190
8. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin. Arch Intern Med 1998:158:1809-1812
9. Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low molecular weight heparin. Arch Intern Med 1998;158:2001-2003
10. Ardeparin and danaparoid for prevention of deep vein thrombosis. The Medical Letter 1997;39:94
11. Bick RL, Haas SK. International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians Consensus Statement of 1995. International Consensus Statement, 1997. Med Clin North Am 1998:82:613-633
12. Hull RD, Pineo GF, Valentine KA. Treatment and prevention of venous thromboembolism. Semin Thromb Hemost 1998;24 (Suppl 1):21-3I
13. Fareed J, Hoppensteadt DA, Jeske WP, et al. The available low molecular weight heparin preparations are not the same. J Clin AppI Thromb Hemost 1997;3:(Suppl. l):38-52
14. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998:114(Suppl):489S-510S
15. Laposata M, Green D, Ban Colt E, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998:122:799-807
16. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995:90:1-7